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esponsibility of InstAbstract Assays based on high-performance liquid chromatography (HPLC) and liquid chromatography
tandem mass spectrometry (LC–MSn) have been developed and validated for the determination and
metabolite identiﬁcation of the bidesmosidic triterpenoid saponin, BTS-1 (3-O-β-D-galactopyranosyl-(1-
2)-[β-D-xylopyranosyl-(1-3)]-β-D-glucuronopyranosyl gypsogenin 28-O-α-L-arabinopyranosyl-(1-3)-β-
D-xylopyranosyl-(1-4)-α-L-rhamnopyranosyl-(1-2)-β-D-fucopyranoside), in rat plasma. The assay was
successfully applied to a pharmacokinetic study in rats given a single oral dose of BTS-1 (400 mg/kg).
The results indicated that the compound was rapidly absorbed (Tmax¼1.2870.29 h, Cmax¼37.475.6 mg/
mL) and slowly eliminated (t1/2¼13.276.6 h). In addition, secondary glycosides and aglycones of BTS-1
were detected and identiﬁed. Since these metabolites are known to be active α-glucosidase inhibitors, they
probably play an important role in mediating the pharmacological effects of the saponin.
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osidic triterpenoid saponin BTS-1 in rat plasma 175Pharmacokinetic study and metabolite identiﬁcation of the bidesm1. Introduction
Triterpenoid saponins, a large category of secondary plant metabolites,
are believed to be the main constituents of many traditional Chinese
medicines (TCM) and are considered responsible for numerous
pharmacological effects1. One such compound known as BTS-1 with
the chemical name 3-O-β-D-galactopyranosyl-(1-2)-[β-D-xylopyrano-
syl-(1-3)]-β-D-glucuronopyranosylgypsogenin 28-O-α-L-arabino-
pyranosyl-(1-3)-β-D-xylopyranosyl-(1-4)-α-L-rhamnopyranosyl-
(1-2)-β-D-fucopyranoside (Fig. 1) is isolated from the roots of
Gypsophila oldhamiana (family Caryophyllaceae), a plant widely
distributed in the Northern regions of China. The roots have been
used as an alternative to the roots of Stellria dichotoma var.
Lanceolata Bge (Yin-Chai-Hu), the most common TCM for the
treatment of fever, consumptive disease and diabetes2.
The triterpenoid saponins of the roots of G. oldhamiana, which
contain BTS-1 as a major compound, are known to be oleanane-
type, some of which are 3-O-monoglucosides, 28-O-monogluco-
sides and 3,28-O-bidesmosides3–5. These saponins have been
reported to exhibit anticancer and antidiabetic effects3,6,7. In our
previous research, the 28-O-monoglucosidic saponins and their
alycones were shown to be the main constituents responsible for
α-glucosidase inhibitory activity, while the 3,28-O-bidesmosidic
saponins were found to be without this type of activity3. Further-
more, we found that the content of the monoglucosidic saponins
was much lower than that of the 3,28-O-bidesmosidic saponins.
In order to understand the pharmacological effects of the roots
of G. oldhamiana, it is important to determine whether orally
administered 3,28-O-bidesmosidic saponins are absorbed from the
intestine and metabolized to their monoglucosidic saponins or
aglycones. To this end, we carried out a pharmacokinetic study of
BTS-1 in rat using a fully validated liquid chromatography mass
spectrometric assay and in addition identiﬁed its metabolites.2. Experimental
2.1. Chemicals and reagents
The reference standards were isolated from G. oldhamiana in our
laboratory and their structures were fully characterized using chemical
and spectroscopic methods (UV, IR, NMR and MS). The purity of the
standards was498.0% as determined by HPLC. The internal standard
(IS), glycyrrhizic acid (purity498.0%, Fig. 1) was obtained from the
TCM Institute of Chinese Materia Medica (Nanjing, China). Water was
puriﬁed using a Milli-Q50 SP water puriﬁcation system (Millipore,
MA, USA). HPLC-grade acetonitrile was purchased from TEDIA
Company (Tedia Fairﬁeld, OH, USA). The other reagents were of
analytical purity and used as received.Figure 1 Chemical structures of2.2. Animals
The animal pharmacokinetic study was approved by the Animal
Ethics Committee of China Pharmaceutical University, Nanjing,
China. Male Sprague–Dawley rats (weight 180–220 g) were
bought from the Shanghai SIPPR/BK Experimental Animal Co.,
Ltd. The rats were maintained in an air-conditioned animal house
at 2272 1C and a relative humidity of 50710%. Water and food
(laboratory rodent chow, Nanjing, China) were allowed ad libitum.
The animals were acclimatized to the facilities for a week and then
fasted with free access to water for 12 h prior to an experiment.2.3. Sample collection
Rats were administrated an oral dose of 400 mg/kg BTS-1
suspended in an aqueous solution of 0.5% carboxymethylcellulose
sodium. Blood samples (200 μL) were collected from the oculi
chorioideae vein into heparinized Eppendorf tubes before dosing
and at 0.084, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 32, 40 and 48 h
following the dose. Plasma samples were obtained by centrifuging
at 4000 rpm for 10 min and frozen at −20 1C pending analysis.2.4. Sample preparation
Plasma samples (50 μL) were spiked with 10 μL IS and extracted
for 6 min with 1 mL n-butanol. After centrifugation (4000 rpm,
5 min), the supernatant was transferred to another vial and
evaporated to dryness under a slow stream of nitrogen at room
temperature. The residue was then reconstituted in 100 μL mobile
phase (acetonitrile: 0.05% aqueous formic acid 30:70 v/v) and
20 μL injected into the HPLC system. Plasma samples prepared
from blood samples taken 1 h after oral administration of BST-1
were used for to investigate metabolites.2.5. Instrumentation and assay conditions
Chromatography was performed on an LC-2010 instrument
(Shimadzu, Japan) equipped with a vacuum degasser, a quaternary
pump, an autosampler and a UV detector set at 210 nm.
Chromatographic separation was carried out on a C18 column
(250 mm 4.6 mm i.d., 5 μm; Welch Materials Inc., USA) main-
tained at 30 1C and protected by a C18 guard column
(7.5 mm 4.6 mm i.d.). The mobile phase consisted of (A)
acetonitrile and (B) 0.05% (v/v) aqueous formic acid delivered at
1 mL/min according to the following linear gradient: 0–8 min 30–
35% A; 8–16 min 35–36% A; 16–46 min 36–53% A; 46–56 min
30% A for re-equilibration. The injection volume was 20 μL.BTS-1 and glycyrrhizic acid (IS).
Jianguang Luo et al.176LC–MSn (n¼2, 3) analysis was performed on an Agilent 1100
HPLC instrument coupled to an LC/MSD trap SL mass spectro-
meter (Agilent Technologies) via an ESI interface operated in the
negative ion mode. Chromatography was carried out as above
except the gradient was extended: 0–8 min 30–35% A; 8–16 min
35–36% A; 16–46 min 36–53% A; 46–62 min 53–75% A; 62–
85 min 75–95%; 85–95 min 30% A for re-equilibration. The MS
conditions were as follows: Nebulizer/drying gas N2 9.0 L/min;
temperature 350 1C, nebulizer pressure 40 psi; ﬂow rate 0.3 mL/
min; scan range 200–1800 amu. Data acquisition was performed
using the Chemstation software (Agilent Technologies).2.6. Preparation of calibration standards and quality control
samples
A stock solution of BTS-1 was prepared in the initial mobile phase
(acetonitrile:0.05% aqueous formic acid, 30:70 v/v) and diluted to
appropriate concentrations to give standard solutions. Calibration
standards containing BTS-1 (0.264, 11.4, 23.8, 62.0, 103.7 and
198.3 mg/mL) and IS (20.37 μg/mL) were prepared by spiking
drug-free plasma (200 μL) with standard solutions (100 mL) and IS
(10 mL). Quality control (QC) samples were prepared indepen-
dently in a similar way at high, medium and low concentrations.
All solutions were stored at 4 1C and found to be stable for 4 days.Figure 2 HPLC chromatograms of BTS-1: (A) blank rat plasma; (B) bla
sample collected 30 min after oral administration of 400 mg/kg BTS-1.2.7. Assay validation
This HPLC method was validated for selectivity, linearity,
accuracy and precision (intra- and inter-day), sensitivity, absolute
recovery and stability. Selectivity was initially investigated by
comparing chromatograms of pooled blank rat plasma with the
same matrix spiked with BTS-1 and IS. Pre-dose plasma samples
were also collected from each rat in the pharmacokinetic study
(n¼6), and the selectivity further evaluated by comparing
chromatograms of pre-dose and post-dose plasma samples.
Linearity was assessed by linear regression of calibration curves
based on peak areas using GraphPad Prism Version 5.01 (La Jolla, CA
92037, USA) with a 1/x2 weighting factor8,9. Plasma BTS-1 concentra-
tions in the pharmacokinetic study were all within this calibration range.
Sensitivity was examined by determination of the limit of
detection (LOD) and lower limit of quantitation (LLOQ) deﬁned
as the concentrations with signal-to-noise ratios of 3 and 10,
respectively. Intra- and inter-day accuracy and precision were
determined by calculation of the means and relative standard
deviations (RSDs) for QC samples (2.64, 23.8 and 103.7 mg/mL)
analysed on four different days.
Absolute recovery was calculated by comparing peak areas of
BTS-1 in QC samples with standard solutions of the same
concentration. Stability of BTS-1 in rat plasma was evaluated in
QC samples stored for 4 days at 4 1C, 2 weeks at −20 1C and after
three freeze–thaw cycles (−20 1C to 24 1C) cycles.nk rat plasma spiked with BTS-1 and glycyrrhizic acid; (C) a plasma
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The analytical method was applied to a pharmacokinetic study in
rats administered a single oral dose of 400 mg/kg BTS-1. Blood
samples were collected before and at 0.083, 0.25, 0.5, 1, 2, 4, 6, 8,
10, 12, 24, 32, 40 and 48 h after oral administration, transferred to
heparinized Eppendorf tubes and centrifuged at 4000 rpm for
10 min. Plasma was then collected and frozen at −20 1C until
analysis. Pharmacokinetic parameters were determined from con-
centration–time data by noncompartmental methods using DAS
Software (version 1.0, Medical College of Wannan, PR China).
Cmax and Tmax values were obtained directly from the data. All
results are expressed as mean7standard deviation (SD).Figure 3 Mean plasma concentration–time proﬁles of BTS-1 in rats
after a single 400 mg/kg oral dose of BTS-1. Data are mean 7SD
(n¼5).3. Results and discussion
3.1. Sample preparation and chromatography
Two methods of sample preparation were tested viz liquid–liquid
extraction (LLE) and protein precipitation. Simple protein precipitation
with either methanol, acetonitrile or other reagents did not provide
satisfactory recovery. LLE using either ethyl acetate, ethyl acetate–
methanol, n-butanol, ethyl acetate–isopropanol or ethyl acetate–acetone
was tested over various extraction times (5, 10, 20 and 30 min) and n-
butanol was found to give the best recovery and reproducibility.
With regard to the chromatography, the inclusion of 0.05%
formic acid in the mobile phase was found to improve peak shape
by inhibiting the ionization of BTS-1. Other parameters were
investigated (column, column temperature, gradient, ﬂow rate and
detection wavelength), and it was found that symmetric peaks and
better resolution was achieved using an Ultimate XB-C18 column
at 30 1C with a ﬂow rate of 1 mL/min.
3.2. Assay validation
Chromatographs of blank rat plasma, blank rat plasma spiked with
analyte and IS and a sample collected 30 min after oral adminis-
tration of BTS-1 are shown in Fig. 2. The retention times of BTS-1Table 1 Intra- and inter-day precision and accuracy for the assay of
Spiked (mg/mL) Intra-day (n¼6)
Meana (μg/mL) Accuracy (%) RSD
103.7 103.270.1 95.7 5.94
23.8 23.370.1 92.5 7.53
2.64 2.3970.13 89.7 9.68
aData are expressed as mean7SD.
Table 2 Recovery and stability (%) of BTS-1 in plasma (n¼6).
Spiked (mg/mL) Recovery (%) RSD (%) Storag
Stabil
103.7 91.872.8 3.65 98.77
23.8 92.473.3 2.48 93.87
2.64 70.075.8 3.83 96.27and IS were 16.8 and 22.5 min, respectively, with baseline
separation and no evidence of interfering peaks. The LOD and
LLOQ were found to be 0.032 and 0.089 mg/mL, respectively.
This method was validated according to the acceptance criteria
of bioanalytical method validation10. The assay was linear
(r240.99) with a typical calibration equation of y¼0.0058x
+0.7133 where x was the concentration of BTS-1, y was the ratio
of peak area of BTS-1 to that of IS. Precision and accuracy data
based on analysis of QC samples are presented in Table 1. Intra-
and inter-day accuracies were in the range 89.7–95.7% and 91.4–
100.5% with RSDo10% in both cases indicating the method has
acceptable reproducibility. Recovery (Table 2) was in the range
70.0–92.4% with RSDo10%. Stability results indicate that there
was no signiﬁcant degradation of the analyte for 4 days at 4 1C and
for up to 2 weeks at −20 1C (Table 2).
3.3. Pharmacokinetic study
The mean plasma concentration–time proﬁles of BTS-1 (n¼5)
after a single oral dose are shown in Fig. 3 with corresponding
pharmacokinetic parameters presented in Table 3. The mean CmaxBTS-1 in plasma.
Inter-day (n¼4)
(%) Meana (μg/mL) Accuracy (%) RSD (%)
102.170.6 100.5 6.46
22.170.8 95.7 8.09
2.0670.45 91.4 8.17
e at 4 1C Freeze–thaw cycles
ity (%) RSD (%) Stability (%) RSD (%)
2.4 2.54 95.274.3 4.19
3.5 2.18 92.873.7 3.68
4.8 3.46 91.675.4 4.85
Jianguang Luo et al.178and Tmax values, 37.475.6 mg/mL and 1.2870.29 h respectively,
were obtained directly from the results. Plasma concentration
declined with a t1/2 of 13.276.6 h. These results indicate that
BTS-1 is rapidly absorbed and eliminated slowly in rats.3.4. Identiﬁcation of metabolites
Tandem mass spectrometric fragmentation behavior of saponins
has been extensively investigated11–13, allowing the characteriza-
tion of unknown compounds in the absence of reference standards.
In the present study, ionization in the negative ion mode was
found to give greater signal intensity of the triterpenoid saponinsFigure 4 Total ion current (TIC) chromatograms of BTS-1 metabolites i
BTS-1. Numbers 2–5 denote compounds (see Fig. 5).
Table 4 Retention times and LC–MSn data for metabolites in rat pl
No. tR (min) [M–H]
-
1 18.4 1495.6
2 or 2' 19.2 1363.9
3 26.3 939.6
4 27.6 807.4
5 28.2 1025.0
6 48.5 470.1
Table 3 Mean pharmacokinetic parameters for BTS-1 in rats
(n¼5) after a single 400 mg/kg oral dose.
Parameter Value (mean7SD)
Tmax (h) 1.2870.29
Cmax (mg/mL) 37.475.6
Vd (L) 43.073.4
Cltot (L/h) 3.3070.26
t1/2 (h) 13.1976.58
AUC (0−t) (mg/mL  h) 121.8716.8
AUC (0−∞) (mg/mL  h) 138.3713.2
MRT(0−∞) (h) 12.871.6than in the positive ion mode.
To identify the metabolites of BTS-1 in rat plasma, LC–MSn
(n¼2, 3) was utilized to analyse blood samples collected 1 h after
oral administration, a time corresponding to the Tmax of BTS-1
(Fig. 3). Total ion current (TIC) chromatograms are shown in
Fig. 4. The main triterpenoid saponins were well detected and
exhibited quasi-molecular [M–H]- ions. Six metabolites were
identiﬁed by comparing retention times and MS/MS data
(Table 4) with those of authentic compounds or literature data3,4.
On the basis of these results, the metabolic pathways shown in
Fig. 5 are proposed. The ﬁndings suggest that some of an orally
administered dose of BTS-1 is quickly metabolized to its
secondary glycosides and aglycone14. These ﬁndings imply that
although 3,28-O-bidesmosidic saponins have been shown to be
inactive as α-glucosidase inhibitors3, they can deglycosylate to
monoglucosidic saponins or their alycones in vivo and thereby
exert important biological effects. Overall, this study shows that
information on the metabolism of TCM is necessary to understand
their pharmacologic activities.4. Conclusions
HPLC and LC–MSn methods have been successfully developed
for the determination of the bidesmosidic triterpenoid saponin
BTS-1 and identiﬁcation of its metabolites in rat plasma. It was
found that BTS-1 is rapidly absorbed and eliminated slowly aftern a rat plasma sample taken 1 h after a single 400 mg/kg oral dose of
asma after a single 400 mg/kg oral dose of BTS-1.
LC–MSn m/z (%)
MS2[1495]: 939(85), 1025 (4), 807 (3)
MS3[1495-939]: 807 (51),563 (42), 469 (34)
MS2[1364]: 939 (18)
MS3[1364-939]: 807 (46),713 (31), 583 (58)
MS2[939]: 807(43), 479 (75)
MS3[940-807]: 763(25), 627 (85)
MS2[807]: 645(43)
MS3[907-645]: 469(23)
MS2[1025]: 961(85), 906 (14)
MS3[1025-961]: 815(27), 661(32), 609(94)
MS2[470]: 255 (95)
Figure 5 Proposed metabolic pathways of BTS-1 in rat.
Pharmacokinetic study and metabolite identiﬁcation of the bidesmosidic triterpenoid saponin BTS-1 in rat plasma 179oral administration to rats, the elimination involving metabolism to
secondary glycosides and aglycones with α-glucosidase inhibitory
activity.
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